In brief, VIP has been shown to significantly attenuate the basal and TNF-α-induced production of pro-inflammatory chemokines and IL-6 in both synovial tissue suspensions and SF from RA patients [98]. This evidence concerns the gene IL6 and rheumatoid arthritis.